HTGC

Business Context and Reporting Period

Company: Hercules Technology Growth Capital, Inc. (Hercules)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: Hercules is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC). It provides debt and equity growth capital to technology-related and life-science companies, primarily focusing on structured mezzanine debt investments coupled with equity warrants.

Key Financial Metrics

Material Changes vs. Prior Period

• Portfolio Growth: The investment portfolio value increased by approximately $59.3 million (21%) from $283.2 million to $342.5 million, driven by $78.4 million in new debt investments and $1.8 million in equity investments.
• Revenue Surge: Net investment income rose significantly to $5.2 million from $0.3 million in Q1 2006. This was primarily due to a 60% increase in interest income ($9.0 million vs. $5.6 million) resulting from a larger loan portfolio.
• Expense Management: Operating expenses remained relatively flat at $4.5 million compared to $4.4 million in the prior year, despite a 53% increase in compensation costs due to headcount growth (19 to 29 employees). Interest expense decreased due to lower average debt balances and reduced interest rates on the Citigroup Facility.
• Capital Structure: Short-term debt increased from $41.0 million to $113.0 million to fund portfolio expansion. Net assets grew substantially due to equity issuances (including an over-allotment exercise) and operational income.
• Realized Gains: The company reported a net realized gain of $290,000 in Q1 2007, contrasting with a net realized loss of $1.7 million in Q1 2006.

Guidance, Outlook, and Risks

• Liquidity and Capital: Management anticipates funding future investment activities through a combination of debt and equity. As of March 31, 2007, the company had approximately $37.0 million in available borrowing capacity under its Citigroup Facility and $41.5 million in cash. Management believes current resources will support investment activities for 5 to 9 months.
• Dividends: The Board declared a quarterly dividend of $0.30 per share. Based on year-to-date data, approximately 80.1% of distributions are expected to be from ordinary income, with 19.9% as a return of capital, though final tax attributes are determined annually.
• Outlook: Management expects 10 to 12 liquidity events (M&A or IPOs) from portfolio companies in the current fiscal year. Two portfolio companies have entered letters of intent for acquisition, and two have filed for IPOs.
• Risks:
  • Concentration Risk: Six portfolio companies represent more than 5% of net assets each, including IKANO Communications (8.4%) and QuatRx Pharmaceuticals (6.6%). Failure of these significant investments could materially impact results.
  • Valuation Uncertainty: Approximately 99% of investments are valued at fair value by the Board of Directors due to the lack of a ready market, introducing estimation risk.
  • Interest Rate Risk: Borrowings are based on LIBOR; while the company may hedge, it is exposed to rate fluctuations.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the Citigroup Facility covenants, specifically the asset coverage ratio (currently 339%) and concentration limits.
• Valuation Methodology: Review the Board's fair value determinations for the 99% of the portfolio lacking a ready market, particularly for the six largest holdings.
• Unfunded Commitments: Assess the impact of $74.7 million in unfunded contractual commitments on future cash flow requirements.
• Warrant Participation: Confirm the status of the 10% warrant participation agreement with Citigroup, which reduces realized gains up to a $3.75 million limit.
• SBIC Leverage: Monitor the drawdown of the $50 million SBA leverage tranche approved for the subsidiary, Hercules Technology II, L.P.